M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Bortezomib after Allografting in Multiple Myeloma: Association between Neurotoxicity and Cyclosporine Treatment
Luisa Giaccone,Roberto Sorasio,Francesca Patriarca,Daniele Mattei,Vittorio Montefusco,Jacopo Peccatori,Fabrizio Carnevale-Schianca,Maria Teresa Petrucci,Giuseppe Milone,Stefano Guidi,Marcello Rotta,Renato Fanin,Paolo Corradini,Mario Boccadoro,Benedetto Bruno +14 more
Journal ArticleDOI
Benign monoclonal gammopathy presenting with severe renal failure.
Paolo Gavarotti,Felice Fortina,Daniela Costa,Giuseppe Verzetti,Valter Redoglia,Mario Boccadoro +5 more
TL;DR: This case suggests that the renal failure complicating a monoclonal gammopathy is not related to its malignancy, and clinical features, as well as kinetic and immunological studies, were consistent with a diagnosis of benign monoconsolidation.
Journal ArticleDOI
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
Elisa Genuardi,Petra Klous,Barbara Mantoan,Daniela Drandi,Martina Ferrante,Federica Cavallo,Beatrice Alessandria,Irene Dogliotti,Daniele Grimaldi,Simone Ragaini,Michele Clerico,Mariella Lo Schirico,Elona Saraci,Mehmet Yilmaz,Gian Maria Zaccaria,Sergio Cortelazzo,Umberto Vitolo,Stefano Luminari,Massimo Federico,Mario Boccadoro,Max van Min,Erik Splinter,Marco Ladetto,Simone Ferrero +23 more
TL;DR: In this article, the authors used Targeted Locus Amplification (TLA) to identify novel gene rearrangements in leukemia and showed that TLA is a promising and reliable NGS-based technology for the identification of novel molecular markers, suitable for further MRD analysis in previously not traceable MCL and FL patients.
Journal ArticleDOI
Bortezomib and Dexamethasone as Maintenance therapy in Relapse/Refractory multiple myeloma Patients
Giulia Benevolo,Alessandra Larocca,Patrizia Pregno,Barbara Botto,Lorella Orsucci,Andrea Evangelista,Antonio Palumbo,Umberto Vitolo,Mario Boccadoro +8 more
TL;DR: Preliminary data suggest that bortezomib/dexametasone MT can improve remission duration and also quality of response with an acceptable toxicity in patients with refractory/relapse MM.
Journal ArticleDOI
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
Antonella Bruzzese,Daniele Derudas,Monica Galli,Enrica Antonia Martino,Stefano Rocco,Concetta Conticello,Catello Califano,Nicola Giuliani,Silvia Mangiacavalli,Giuliana Farina,Alessandra Lombardo,Marino Brunori,Elena Rossi,Elisabetta Antonioli,Roberto Ria,Renato Zambello,Nicola Di Renzo,Giuseppe Mele,Gianpaolo Marcacci,Giuseppe Pietrantuono,Gaetano Palumbo,Nicola Cascavilla,Claudio Cerchione,Angelo Belotti,Clelia Criscuolo,Giuseppina Uccello,Paola Curci,Ernesto Vigna,Francesco Mendicino,Enrico Iaccino,Selena Mimmi,Cirino Botta,D Vincelli,Nicola Sgherza,Angela Bonalumi,Luca Cupelli,Raffaella Stocchi,M. Martini,Stelvio Ballanti,Dominella Gangemi,A. Gagliardi,Barbara Gamberi,Alessandra Pompa,Giovanni Tripepi,Ferdinando Frigeri,Ugo Consolo,Sara Bringhen,Elena Zamagni,Francesca Patriarca,Valerio De Stefano,Francesco Di Raimondo,Salvatore Palmieri,Maria Teresa Petrucci,Massimo Offidani,Pellegrino Musto,Mario Boccadoro,Michele Cavo,Antonino Neri,Fortunato Morabito,Massimo Gentile +59 more
TL;DR: This study confirms that EloRd is a safe and effective regimen for RRMM patients, maintaining benefits across multiple unfavorable subgroups.